Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer

SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the hiring of Jan M. Van Tornout, M.D., MSc., as chief medical officer, and Gordon Schooley, Ph.D., as chief regulatory officer.

Read more:
Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer

BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.

COPENHAGEN, Denmark and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced its achievement of targeted subject enrollment for the third part of a 3-part clinical study to support a U.S. Food and Drug Administration (FDA) De Novo submission for use of The NGAL Test in identifying patients under the age of 22 at risk for Acute Kidney Injury (AKI).

More:
BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.

ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Go here to read the rest:
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy -

Read the original here:
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase shares of its common stock. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio.

See the original post here:
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants

Oyster Point Pharma Announces Operating Expense Streamlining Plan

Plan to Continue to Drive TYRVAYA® Launch with Approximately 150-200 Field-Based Sales Resources

See the article here:
Oyster Point Pharma Announces Operating Expense Streamlining Plan

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first environmental, social and governance (ESG) report, highlighting increased efforts to support a healthy, equitable and sustainable society. The report outlines actions taken to expand access to genetic testing, advance social justice, and increase environmental sustainability.

Read more here:
Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

Beyond Air’s LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide unlimited, on-demand nitric oxide

The rest is here:
Beyond Air’s LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SANTA MONICA, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation and Human Capital Committee of the Company’s Board of Directors has approved the grant of restricted stock units (“RSU”) covering an aggregate of 25,900 shares of common stock to seven hired employees, pursuant to the Company’s 2022 Inducement Equity Incentive Plan (“Inducement Plan”). The RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Go here to see the original:
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications

EMERYVILLE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications. 3D4Makers will convert the powder to filament, offering its first-ever polyimide filament to customers for use across a wide range of applications including aerospace, automotive, and transportation.

Read the original:
Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications